• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Mainz Biomed N.V.

    5/2/25 4:30:22 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MYNZ alert in real time by email
    6-K 1 ea0239810-6k_mainz.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2025

     

    Commission File No. 001-41010

     

    MAINZ BIOMED N.V.

    (Translation of registrant’s name into English)

     

    Robert Koch Strasse 50
    55129 Mainz
    Germany

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

     

     

    Other Events

     

    On or around May 13, 2025, Mainz Biomed N.V. will begin mailing to certain shareholders of record as of the close of business on May 5, 2025, a power of attorney and voting proxy card pursuant to Dutch law, relating to its annual general meeting of shareholders to be held on June 2, 2025. Copies of certain of these documents are attached as Exhibits 99.1, 99.2, and 99.3 hereto.

     

    This current report on Form 6-K and exhibits 99.1, 99.2, and 99.3 hereto are hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-269091).

     

    Exhibit No.   Exhibit
    99.1   Notice of Annual General Meeting
    99.2   Agenda of the Annual General Meeting
    99.3   Voting Proxy Card, and Power of Attorney

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 2, 2025 By: /s/ William J. Caragol
      Name:  William J. Caragol
      Title Chief Financial Officer

     

    2

     

     

     

    Get the next $MYNZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYNZ

    DatePrice TargetRatingAnalyst
    2/14/2025$14.00Buy
    Maxim Group
    11/25/2024Buy → Neutral
    H.C. Wainwright
    11/21/2023Overweight → Neutral
    Cantor Fitzgerald
    6/21/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $MYNZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Mainz Biomed B.V. with a new price target

      Maxim Group initiated coverage of Mainz Biomed B.V. with a rating of Buy and set a new price target of $14.00

      2/14/25 8:10:14 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed B.V. downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Mainz Biomed B.V. from Buy to Neutral

      11/25/24 7:48:30 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed B.V. downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Mainz Biomed B.V. from Overweight to Neutral

      11/21/23 7:33:52 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Financials

    Live finance-specific insights

    See more
    • Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

      Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property ("IP") for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorec

      2/21/23 3:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers

      Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Biomarkers Demonstrated Unique Ability to Identify Curable Precancerous Colonic Polyps as well as Curable Early-Stage Colorectal Cancer BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. ("TTS") to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert,

      1/5/22 3:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mainz Biomed N.V.

      SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

      10/7/24 4:47:27 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mainz Biomed N.V. (Amendment)

      SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

      2/13/24 2:39:04 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Mainz Biomed N.V.

      SC 13G - MAINZ BIOMED N.V. (0001874252) (Subject)

      3/1/23 6:38:43 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mainz Biomed Enters into Technology Partnership with EDX Medical Group

      BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

      4/29/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

      BERKELEY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first quarter of 2025, and provided an outlook on its path to FDA premarket approval.   During the first quarter of 2025: Path to FDA premarket approval: The Company enrolled the first patient into its feasibility study eAArly DETECT 2, which evaluates the Mainz Biomed's next-generation colorectal cancer (CRC) test, integrating a portfolio of proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test. The study is

      4/28/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

      Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus Strategic partnerships with industry leaders mark key progress Company highlights its early accomplishments for 2025 BERKELEY, Calif. and MAINZ, Germany, April 01, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the year ended December 31, 2024, a summary on 2024 accompli

      4/1/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    SEC Filings

    See more
    • Amendment: SEC Form F-1/A filed by Mainz Biomed N.V.

      F-1/A - MAINZ BIOMED N.V. (0001874252) (Filer)

      5/14/25 4:20:36 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form F-1 filed by Mainz Biomed N.V.

      F-1 - MAINZ BIOMED N.V. (0001874252) (Filer)

      5/14/25 8:43:39 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Mainz Biomed N.V.

      6-K - MAINZ BIOMED N.V. (0001874252) (Filer)

      5/2/25 4:30:22 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Leadership Updates

    Live Leadership Updates

    See more
    • Mainz Biomed Enters into Technology Partnership with EDX Medical Group

      BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

      4/29/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

      BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the Company in the development and dissemination of messaging focused on the importance of early detection of colorectal cancer. "We are excited about Petra joining our team as Brand Ambassador. Her broad and deep experience will be invaluable to us as we bring our next generation colorectal cancer screening product to market, with the

      9/18/24 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

      Former Natera Manager will oversee all aspects of sales and support in EMEA, ensuring the continued commercialization of ColoAlert® across the region BERKELEY, Calif. and MAINZ, Germany, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is proud to announce the appointment of Tarrin Khairi-Taraki as Vice President of Commercial Operations, EMEA. Tarrin will play a pivotal role in steering Mainz Biomed's continued success, focusing on the commercialization of its flagship product, ColoAlert® — a highly effective and user-friendly at-home detection test f

      10/26/23 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care